Founder & CEO Laura Niklason, M.D., Ph.D., to deliver invited talk on engineering the microenvironment to accelerate vascular regeneration. – Two additional presentations to cover first-in-human Phase 2a study design and preclinical results for Humacyte’s investigational coronary tissue…
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the three…
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered…
We’ve pioneered a scalable bioengineering platform that transforms human cells into universally implantable human tissues being investigated for the treatment of injury, disease, and chronic conditions, across a wide range of clinical needs. The goal is to provide regenerative biologic tissues that are available off-the-shelf, with low rates of infection, and universally implantable.
Learn more
During the decellularization stage of the proprietary manufacturing process, cells are removed from bioengineered tissues while key proteins are retained. These proteins signal the patient’s own cells to bind to the extracellular matrix (ECM), and proliferate.1 Over time, the bioengineered tissue becomes the patient’s own tissue.1
Learn moreWe are currently building an extensive portfolio and pipeline of investigational product candidates to address a broad range of clinical needs - all built on the foundational science of our Acellular Tissue Engineered Vessel platform.
Learn more
A first-of-its-kind
human-derived biologic vessel.
Biologics License Agreement (BLA) approved by U.S. FDA December, 2024
These are investigational uses that have not been approved by any health authority. Safety and efficacy have not been established and there is no guarantee that pipeline products or investigational uses will receive approval from health authorities.
